Despite tremendous efforts to improve the methodology for constructing flavivirus infectious cDNAs, the manipulation of flavivirus cDNAs remains a difficult task in bacteria. Here, we successfully propagated DNA-launched type 2 dengue virus (DENV2) and Japanese encephalitis virus (JEV) infectious cDNAs by introducing seven repeats of the tetracycline-response element (7¾TRE) and a minimal cytomegalovirus (CMVmin) promoter upstream of the viral genome. Insertion of the 7¾TRE-CMVmin sequence upstream of the DENV2 or JEV genome decreased the cryptic E. coli promoter (ECP) activity of the viral genome in bacteria, as measured using fusion constructs containing DENV2 or JEV segments and the reporter gene Renilla luciferase in an empty vector. The growth kinetics of recombinant viruses derived from DNA-launched DENV2 and JEV infectious cDNAs were similar to those of parental viruses. Similarly, RNA-launched DENV2 infectious cDNAs were generated by inserting 7¾TRE-CMVmin, five repeats of the GAL4 upstream activating sequence, or five repeats of BamHI linkers upstream of the DENV2 genome. All three tandem repeat sequences decreased the ECP activity of the DENV2 genome in bacteria. Notably, 7¾TRE-CMVmin stabilized RNA-launched JEV infectious cDNAs and reduced the ECP activity of the JEV genome in bacteria. The growth kinetics of recombinant viruses derived from RNA-launched DENV2 and JEV infectious cDNAs displayed patterns similar to those of the parental viruses. These results support a novel methodology for constructing flavivirus infectious cDNAs, which will facilitate research in virology, viral pathogenesis and vaccine development of flaviviruses and other RNA viruses.
INTRODUCTION
Most flaviviruses are transmitted by mosquito or tick vectors and cause serious human and animal diseases (Lindenbach et al., 2013; Pierson & Diamond, 2013) . Some members of the genus Flavivirus are re-emerging global health threats, especially in urban areas of developing countries (Mackenzie et al., 2004; Simmons et al., 2012) . Flaviviruses include Dengue virus (DENV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Yellow fever virus (YFV) and Tickborne encephalitis virus (TBEV). There are four different serotypes of DENV, DENV1-4. DENV has been circulating in over 100 countries, and an estimated 2.5610 9 people live in areas in which dengue is epidemic (Guzmán & Kouri, 2002 Pinheiro & Corber, 1997; Simmons et al., 2012) . DENV infection often leads to dengue fever, dengue haemorrhagic fever and dengue shock syndrome (Gubler, 1989; Halstead, 1980; Pinheiro, 1989; Simmons et al., 2012) . JEV can cause permanent neuropsychiatric sequelae and results in 10 000 deaths from an estimated 175 000 cases each year (van den Hurk et al., 2009) . While vaccines are available for JEV (van den Hurk et al., 2009) , there is no clinically approved vaccine or antiviral agent yet available for DENV.
Flaviviruses are single-strand positive-stranded RNA viruses with 10.5 to 11 kb genomic RNA. Upon flavivirus infection of host cells, the polyprotein is translated from viral RNA at the endoplasmic reticulum and processed into three structural proteins (C, prM and E) and seven non-structural proteins (NS1-5) by host and viral proteases, initiating viral RNA replication (Chambers et al., 1990; Falgout et al., 1991) . Introduction of flavivirus genomic RNA into susceptible cell lines can result in the production of infectious virus particles (Ada & Anderson, 1959) . This phenomenon has prompted the study of flavivirus virology via introduction of flavivirus genomic RNA that has been transcribed in vitro from flavivirus infectious cDNA. Such reverse genetics is a powerful method for studying the viral replication of positive-stranded RNA viruses (Boyer & Haenni, 1994) .
Although reverse genetics has been shown to be a useful tool to study flavivirus, the manipulation of flavivirus infectious cDNA is largely hampered by its instability in bacteria (reviewed by: Blaney et al., 2006; Ruggli & Rice, 1999; Ward & Davidson, 2008) . Several methodologies were developed to overcome the toxicity of flavivirus cDNAs in bacteria. An earlier approach was based on the separation of the virus genome into two plasmids followed by in vitro ligation and RNA transcription (Audsley et al., 2011; Beasley et al., 2005; Kapoor et al., 1995; Mandl et al., 1997; Rice et al., 1989; Sumiyoshi et al., 1992) . Improved approaches have been developed to propagate flavivirus infectious cDNAs in bacteria, e.g. use of specific cloning vectors or bacterial strains (Bredenbeek et al., 2003; Lai et al., 1991; Schoggins et al., 2012; Sriburi et al., 2001; Suzuki et al., 2007; Yun et al., 2003; Zhang et al., 2001; Zhao et al., 2005) , use of yeast cells to assemble infectious cDNAs (Kelly et al., 2010; Polo et al., 1997) , and introducing mutations into flavivirus cDNAs to reduce cryptic E. coli promoter activity (Pu et al., 2011) . Recently, two novel bacterium-free methods have been developed to generate Kunjin virus (KUNV) (Edmonds et al., 2013) and DENV (Siridechadilok et al., 2013) infectious cDNAs in vitro to avoid the toxicity of flavivirus cDNA in bacteria. However, the bacterium-free methods are not able to provide homogeneous infectious flavivirus cDNA plasmids for further manipulation.
Most of the reported flavivirus infectious cDNA clones are of the RNA-launched type. RNA-launched flavivirus infectious cDNA clones must be transcribed into RNA in vitro and then transfected into cells and undergo translation of transfected viral RNAs, initiating virus replication and synthesis of virions. In contrast, infectious virions are directly synthesized by susceptible cells transfected with DNA-launched flavivirus infectious cDNA clones, which enter into cells and undergo viral RNA synthesis driven by eukaryotic promoters, e.g. cytomegalovirus (CMV) promoter, upstream of the flavivirus genome. To date, only a few DNA-launched flavivirus infectious cDNA clones have been reported, e.g. KUNV (Khromykh et al., 2001) , JEV , WNV (Pierson et al., 2005) and DENV (Usme-Ciro et al., 2014) . It has been speculated that this paucity may be due to the instability of infectious cDNA clones in bacteria caused by the CMV promoter, as the CMV promoter has prokaryotic promoter activity in bacteria (Antonucci et al., 1989; Davis & Huang, 1988; Lewin et al., 2005) . Consistent with the fact that the CMV promoter has cryptic E. coli promoter (ECP) activity in bacteria, it has been suggested that the spurious transcription of virus genes is turned on by the upstream CMV promoter, resulting in the cryptic expression of toxic viral proteins, which causes extremely slow growth of bacteria harbouring the flavivirus infectious cDNA clones . It has been reported that the JEV genome contain several potential splice sites, possibly making DNA-launched JEV infectious cDNAs difficult to express in the nucleus , which might explain why DNA-launched infectious cDNAs are not widely available.
Previously, the viral protein expression from several cryptic ECPs in the flavivirus genome was shown to be responsible for the instability of DENV2 and JEV cDNAs in bacteria (Pu et al., 2011) . We further introduced mutations into the genomes of DENV2 and JEV, and successfully obtained RNA-launched DENV2 and JEV infectious cDNA clones, e.g. DENV2-6M (with six sets of silent mutations within C-prM-E-NS1), DENV2-8M (with two more sets of silent mutations within the capsid region than has DENV2-6M) and JEV-A90C (A90C mutation within the 59UTR). We sought to develop a convenient methodology for constructing stable flavivirus cDNA. In the present study, we developed a novel method to prepare DENV2 and JEV infectious cDNA clones without altering the sequence of the viral genome. Either DNA-or RNA-launched DENV2 or JEV infectious cDNA clones were generated by inserting various tandem repeat sequences upstream of the virus genome. The cryptic expression of the DENV2 or JEV proteins was greatly reduced by the upstream tandem repeat sequences, which is related to the increased stability of DENV2 or JEV infectious cDNAs in bacteria. This convenient and feasible method will greatly facilitate studies in virology, viral pathogenesis and vaccine development.
RESULTS
Successful propagation of DNA-launched DENV2 and JEV infectious cDNA clones Based on the knowledge previously gained from constructing RNA-launched DENV2 and JEV infectious cDNA, we sought to establish a convenient DNA-launched infectious cDNA clone driven by the CMV promoter for transient expression. The resulting plasmid, pBR322 origin (10-20 copies per cell), contains a genomic cDNA in which the 59-UTR of the DENV2 genome is located immediately downstream of the CMV promoter and the 39UTR is located just upstream of the anti-genomic sequences of the hepatitis delta virus ribozyme (HDVr). The HDVr sequences ensure the generation of the correct DENV2 39 terminus. The simian virus 40 poly-adenylation signal was inserted at the end of the DENV2 genome to stabilize the viral RNA in the cells.
It has been demonstrated that infectious JEV or hepatitis C virus (HCV) virions could be successfully produced from the infectious cDNA clones driven by a minimal CMV (CMVmin) promoter or a tetracyclineregulated CMVmin promoter (pTight promoter) (Cai et al., 2005) , respectively. The pTight promoter has seven repeated tetracycline-response elements (76TRE) located upstream of the CMVmin promoter sequence. Therefore, we attempted to construct a DNA-launched DENV2 infectious cDNA clone by inserting either the CMVmin promoter or the pTight promoter upstream of the DENV2-6M genome (strain PL046). As a result, we successfully obtained a DENV2 infectious cDNA clone driven by a pTight promoter, pTight-DENV2-6M, but failed to acquire an intact infectious clone with a CMVmin promoter (in the absence of 76TRE). This phenomenon suggests that the 76TRE sequence may stabilize the pTight-DENV2-6M cDNA. These results prompted us to construct a DNA-launched DENV2 cDNA clone without silent mutations within the DENV2 genome. We decided to construct the DENV2 cDNAs derived from strain 16681 (Kinney et al., 1997) because we found that the 16681 strain viruses have a better replication capacity than the PL046 strain viruses (data not shown).
To test our hypothesis, we constructed a new DNA-launched DENV2 infectious cDNA clone, pTight-DENV2 (Fig. 1a) , by replacing the Rluc-Neo-IRES sequences within pTightDENV2Rep (Yang et al., 2013) with a cDNA fragment comprising the DENV2 structural gene, C-PrM-E. Notably, we found that the pTight-DENV2 infectious clone was obtained without apparent stability issues in bacteria.
To determine whether the DNA-launched DENV2 infectious cDNA clones were infectious, HEK293 cells were transfected with pTight-DENV2 in combination with the pTet-Off plasmid. The pTet-Off plasmid expresses a tet-responsive transcriptional activator that drives the expression of DENV2 under pTight promoters in HEK293. A substantial cytopathic effect (CPE) was observed in HEK293 cells 6 days after transfection with pTight-DENV2 (Fig. 1b) . Indirect immunofluorescence assay (IFA) was used to detect cells expressing the DENV2 prM proteins in transfected HEK293 cells. DENV2 prM proteins could be detected in cells 4 days after transfection with pTight-DENV2 plasmids. Plaque morphologies of the recombinant DENV2 were indistinguishable from the parental viruses (Fig. 1c) . To further quantitatively evaluate the infectivity of virions derived from the pTight-DENV2 plasmids, the titres of the viruses synthesized from HEK293 cells transfected with these plasmids were measured using a plaque formation assay. The virus derived from the pTight-DENV2 plasmid reached the highest titre (approx. 1610 7 p.f.u. ml
21
) 6 days after transfection (Fig. 1d ). The kinetics of virus growth derived from parental DENV2 or recombinant DENV2 showed that there is no apparent difference in the growth curve of virus replication in BHK21 cells infected by DENV2 or recombinant DENV2 at a m.o.i. of 0.1 (Fig. 1e ).
The same strategy was applied to construct a DNA-launched JEV infectious cDNA clone, pTight-JEV (Fig. 2a) , by replacing the full-length DENV2 genome in the pTight-DENV2 plasmid with the full-length JEV genome. The full-length JEV genome was generated through multiple-fragment homologous recombination of three wild-type JEV cDNA fragments, nucleotides 1-2890, 2802-6831 and 6727-10976, in yeast cells (Polo et al., 1997) . As expected, we successfully obtained pTight-JEV without the A90C mutation. pTight-JEV plasmids were transfected into BHK21 cells to determine if pTight-JEV is an infectious clone. CPE was observed in BHK21 cells 2 days after transfection with pTight-JEV (Fig. 2b) . Most of the BHK21 cells were positive for IFA staining with antibody against JEV envelope proteins 3 days after transfection with pTight-JEV. Plaque morphologies of the recombinant JEV were similar to those of the parental viruses (Fig. 2c) . JEV virions were efficiently produced, with the highest titre (approx. 1610 7 p.f.u. ml
) reached 3 days after transfection with pTight-JEV plasmids in BHK21 cells (Fig. 2d ). The kinetics of virus growth derived from parental JEV and recombinant JEV were compared and no apparent difference in the growth curve of virus replication in BHK21 cells infected by parental JEV and recombinant JEV at a m.o.i. of 0.1 was observed (Fig. 2e) .
Various upstream tandem repeat sequences downregulate the cryptic E. coli promoter activity of the DENV2 and JEV genomes in bacteria
Since we have previously shown that cryptic expression of the DENV2 and JEV genomes is toxic to bacteria, we intended to determine whether the stabilizing effect of the pTight promoter resulted from its ability to downregulate cryptic ECP activity in bacteria. Because the pTight promoter has seven tetracycline-response elements and a CMVmin promoter, we used 76TRE-CMVmin to indicate the pTight promoter. The 76TRE-CMVmin along with other tandem repeat sequences, e.g. 56GAL4 and 56BamHI, was individually introduced upstream of the DENV2-Luc or JEV-Luc constructs (Fig. 3a) . DENV2-Luc and JEV-Luc were generated by fusing nucleotides 1-300 and 1-150 of the DENV2 and JEV genome, respectively, to the Renilla luciferase gene and have been shown to express the fusion protein in bacteria since two cryptic ECPs were found within nucleotides 1-300 and 1-150 of the DENV2 and JEV genomes, respectively (Pu et al., 2011) . DENV2-Luc or JEV-Luc constructs harbouring various tandem repeat sequences were then transformed into the bacterial cells. When compared with the luciferase activity of the DENV2-Luc constructs without upstream tandem repeat sequences, all tandem repeat sequences tested decreased the luciferase activity of the DENV2-Luc construct in bacteria, although the inhibitory effect of 56GAL4 and 56BamHI on downstream ECPs of DENV2 was not as prominent as that of 76TRE-CMVmin (Fig. 3b) . In the case of JEV, only 76TRE-CMVmin could moderately decrease the luciferase activity from JEV-Luc in bacteria (Fig. 3c) .
RNA-launched DENV2 and JEV infectious cDNA clones were generated by inserting upstream tandem repeat sequences
To further explore their stabilizing capability, tandem repeat sequences were inserted upstream of the SP6 promoters in RNA-launched DENV2 and JEV infectious cDNA based on the DENV2-6M and JEV-A90C cDNA obtained previously (Pu et al., 2011) . Silent mutations on DENV2-6M and JEV-A90C were removed by replacing the mutation-containing fragments with wild-type DENV2 and JEV cDNA fragments. Interestingly, it was convenient to introduce 76TRE-CMVmin, 56GAL4 or 56BamHI sequences into the upstream DENV2 genome to obtain pTight-SP6-DENV2, pGAL4-SP6-DENV2 and pBamHI-SP6-DENV2, respectively (Fig. 4a) . On the contrary, we were only able to insert the 76TRE-CMVmin, and not the 56GAL4 or 56BamHI, tandem repeat sequence upstream of the wild-type JEV genome to generate the RNA-launched JEV cDNA clone, pTight-SP6-JEV (Fig. 5a ). This observation is consistent with the results shown in Fig. 3(c) that only the 76TRE-CMVmin, and not the 56GAL4 or 56BamHI, tandem repeat sequence was able to downregulate the downstream ECP activity of the JEV cDNA fragment in bacteria.
RNA-launched full-length DENV2 and JEV cDNA clones containing upstream tandem repeat sequence are infectious
To determine whether pTight-SP6-DENV2, pGAL4-SP6-DENV2, pBamHI-SP6-DENV2 and pTight-SP6-JEV were infectious, in-vitro-transcribed viral RNAs derived from those plasmids were transfected into BHK21 cells. Substantial CPE was observed in the BHK21 cells on the fourth day after transfection with RNA transcripts derived from DENV2 with different tandem repeat sequences, and on the third day posttransfection with JEV with 76TRE-CMVmin. The infectivity was further confirmed by IFA measurement of prM or envelope protein expression in BHK21 cells transfected by invitro-transcribed DENV2 and JEV RNAs, respectively. Both DENV2 prM and JEV envelope proteins were detected in the cells 1 day after transfection, and the spreading of DENV2 prM or JEV envelope protein-positive cells started 2 days after transfection (Figs 4b and 5b) . Plaque morphologies and the viral growth curve of recombinant DENV2 and JEV from BHK21 cells were indistinguishable from those of their respective parental viruses (Figs 4c and 5c) . A plaque formation assay of the medium recovered from BHK21 cells transfected with DENV2 or JEV in-vitro-transcribed RNA showed that the highest titres of both DENV2 (~16 10 7 p.f.u. ml
) and JEV (~1610 8 p.f.u. ml
) were achieved on day 3 after transfection (Figs 4d and 5d) . The viral titre of both DENV2 and JEV dropped gradually as the cell population decreased due to CPE. C  E  NS1  NS3  NS5  NS4B  2A  4A  2B  prM   C  E  NS1  NS3  NS5  NS4B  2A  4A  2B  prM   C  E  NS1  NS3  NS5  NS4B  2A  4A  2B 1994). Equal amounts of plasmids containing DNA-or RNA-launched DENV2 or JEV infectious cDNA with different tandem repeat sequences were transformed into bacterial cells (strain C41) and plated on 26 YT with ampicillin (15 mg ml
) at 25 u C for 2 days to avoid satellite colonies. The results indicated that bacteria transformed with pTight-SP6-DENV2 or pTight-DENV2 produced significantly more colonies than those transformed with DENV2-6M, but slightly fewer than those transformed with DENV2-8M (Fig. 6a) . There was no significant difference in the colony numbers among bacteria transformed with pGAL4-SP6-DENV2, pBamHI-SP6-DENV2 and DENV2-6M. The bacteria transformed with DNA-and RNAlaunched JEV infectious cDNA clone, pTight-JEV and pTight-SP6-JEV, respectively, produced three-to fourfold more colonies than those transformed with JEV-A90C (Fig. 6b) .
The stability of cloned DNA-or RNA-launched DENV2 infectious cDNAs was further accessed by repeated subculture in E. coli strain C41. C41 was transformed with those DNA-or RNA-launched DENV2 infectious cDNAs and the colonies grown (all homogeneous colonies) were selected at 30 u C on 26 YT agar plates containing ampicillin (15 mg ml 21 ) 1 day after transformation. Four colonies were picked, mixed and incubated at 30 u C in liquid 26 YT medium containing ampicillin (15 mg ml
) for 1 day more.
The saturated 26 YT medium containing bacteria harbouring DENV2 plasmids was subjected to plasmid purification. The purified DENV2 infectious cDNA plasmids were transformed into bacteria and grown on 26 YT-ampicillin agar plates. Four colonies grown on an agar plate were picked and mixed for the same growth testing cycle three times. After three growth cycles, two clones were amplified and DENV2 infectious cDNA plasmids were purified (~0.5 mg per10 9 cells), and their integrity was confirmed by using two sets of digestion with restriction enzyme to make sure no transposon insertion and DNA rearrangement had occurred during the passages. The integrity of DNA-or RNA-launched DENV2 infectious cDNAs could be maintained for at least three passages of subcultures. The kinetics of virus spreading derived from either the original or the third passage of DENV2 infectious cDNAs displayed similar patterns (Fig. S1a, c, d , e, available in the online Suplementary Material).
The colonies (all homogeneous but smaller) derived from pTight-JEV or pTight-SP6-JEV plasmids were under the same selection condition as DENV2 infectious cDNA clones. Four colonies grown on an agar plate were picked, mixed, cultured and amplified on 26 YT agar plates. The bacteria grown were harvested and subjected to plasmid purification. The purified pTight-SP6-JEV or pTight-JEV plasmids (~0.2 mg per 10 9 cells) were transformed into bacteria and four colonies grown on agar plates were picked, mixed and grown for two more cycles under the same conditions as for amplifying pTight-JEV or pTight-SP6-JEV. After three growth cycles, the integrity of purified JEV plasmids was confirmed by restriction digestion. The kinetics of virus spreading derived from either the original or the third passage of JEV infectious cDNAs displayed similar patterns (Fig. S1b, f) .
DISCUSSION
In this report, we discovered a novel method to propagate DNA-or RNA-launched DENV2 and JEV infectious cDNAs without altering viral genomic sequences. Instead of using silent mutations that have been shown to efficiently stabilize DENV2 and JEV infectious cDNAs in bacteria, we introduced the 76TRE-CMVmin tandem repeat sequence upstream of the DENV2 or JEV genome to stabilize the infectious cDNAs. Notably, the other two tandem repeat sequences, 56GAL4 and 56BamHI, also stabilized the DENV2 genome. Infectious virions were efficiently produced in cells transfected with either DNA-launched DENV2 or JEV infectious cDNA plasmids or in-vitrotranscribed RNAs derived from RNA-launched infectious cDNA plasmids. Therefore, the novel methods described in this paper provide a convenient and alternative way to construct flavivirus infectious cDNA clones.
In several attempts to construct a DNA-launched DENV2 infectious cDNA clone, we failed to replace the SP6 promoter with CMV or CMVmin in the DENV2-6M or DENV2-8M plasmid, which could be steadily propagated in bacteria. These results suggest that the CMV or CMVmin promoter located upstream of the DENV2 genome caused the instability of the DNA-launched DENV2 cDNA plasmid in bacteria. This observation is consistent with several previous reports that the CMV promoter has prokaryotic promoter activity in E. coli (Antonucci et al., 1989; Davis & Huang, 1988; Lewin et al., 2005) . The effect of 76TRE-CMVmin on the stability of DNA-launched DENV2 and JEV infectious cDNA clones (Figs 1 and 2 ) raised questions regarding the underlying mechanism of its stabilizing effect on flavivirus cDNA in bacteria. DENV2 or JEV ECP activity analyses showed that 76TRE-CMVmin could readily downregulate adjacent ECP activities from DENV2 or JEV cDNA fragments (Fig. 3b, c) . These results suggest that 76TRE-CMVmin reduces the cryptic ECP activity of the downstream DENV2 or JEV genome, which in turn stabilizes infectious cDNA clones in bacteria. One intriguing observation revealed that two tandem repeat sequences, 56GAL4 and 56BamHI, stabilized RNA-launched DENV2 but not JEV infectious cDNA clones in bacteria. The 76 TRE-CMVmin tandem repeat sequence was the only one that stabilized the RNA-launched JEV infectious cDNA clone. The stabilization effect of tandem repeat sequences is explained by the result that their inhibitory effect on the ECP activity of DENV2 was observed when either of the other two tandem repeat sequences, 56GAL4 and 56BamHI, was inserted upstream of the DENV2 genome, although to a lesser extent than for the 76TRE-CMVmin sequence (Fig. 3b) . The 76TRE-CMVmin but not the 56GAL4 or 56BamHI tandem repeat sequence apparently reduced the ECP activity of JEV (Fig. 3c) , which is consistent with the failure of the 56GAL4 or 56BamHI tandem repeat sequence to reduce the toxicity of JEV cDNA in bacteria. The other observation showed that 76TRE and 76TRE-CMVmin, but not 56BamHI-CMVmin or 56GAL4-CMVmin, reduced the ECP activity of JEV ( S2), suggesting the essential role of 76TRE but not CMVmin in inhibiting the downstream ECP activity of JEV. The tandem repeat sequence 76TRE has seven copies of the TRE DNA element (19 nt), whereas the lengths of each GAL4 and BamHI DNA element are 16 and 12 nt, respectively. Thus, a question is raised as to whether the differences in reducing the ECP activity of JEV among 76TRE, 56GAL4 and 56BamHI are due to the differences in the copy numbers and/or lengths of each DNA element. Further study is needed to explain the difference in downregulating ECP activity of various tandem repeat sequences.
As shown in Fig. 6(a) , the colony numbers of bacteria transformed with pGAL4-SP6-DENV2 and pBamHI-SP6-DENV2 were comparable to those of bacteria transformed with DENV2-6M. Notably, the colony number of the bacteria transformed with the pTight-SP6-DENV2 plasmid was more than that of the bacteria transformed by DENV2-6M, but slightly less than that of the bacteria transformed by DENV2-8M. These results suggest that the introduction of tandem repeat sequences upstream of the DENV genome has a similar effect on the stability of DENV infectious cDNA clones in bacteria to introducing six to eight sets of silent mutations into the DENV genome. Moreover, the colony number of bacteria transformed with the pTight-SP6-JEV plasmid was approximately three-to fourfold greater than that of bacteria transformed with the JEV-A90C plasmid, which harbours a single nucleotide silent mutation near the 59UTR of the JEV genome (Fig. 6b ). Previously we have predicted two possible ECPs within nucleotides 1-150 of the JEV genome, and the A90C mutation was suggested to reduce only one of the two predicted ECPs (Pu et al., 2011) . Therefore, the substantially lower colony number of bacteria transformed with JEV-A90C than of bacteria transformed with a stable plasmid, such as the HCV1b replicon (Fig. 6b) , might possibly be due to the cryptic expression of viral proteins from the other ECP. The drastic increase in the colony number of bacteria transformed with pTight-SP6-JEV may be due to the efficient reduction of the activity of both ECPs in the JEV genome by the 76TRE-CMVmin tandem repeat sequence.
The fact that the 76TRE-CMVmin tandem repeat sequence has a stronger effect in inhibiting downstream DENV2 or JEV ECP activity than does 56GAL4 or 56BamHI implies that the inhibitory effect may depend on the characteristics of the tandem repeat sequences and/ or the downstream ECP. In fact, tandem repeat sequences are known to regulate gene transcription by binding to transcription factors, changing chromatin structure or altering DNA conformation (Gemayel et al., 2010) . Thus, we speculated that 76TRE-CMVmin might alter the conformation around the ECPs in the DENV2 or JEV genomes, inhibiting their ECP activities. The fact that 56GAL4 and 56BamHI failed to reduce the stability of the JEV genome is possibly due to their inability to induce sufficient conformational change around the ECPs in the JEV genome and/or to some other unknown mechanism, resulting in their inability to inhibit the expression of toxic viral proteins in E. coli.
The novel approach presented herein will help guide both basic and applied viral research fields. First, our method for cloning DENV2 and JEV cDNA demonstrates that upstream tandem repeat sequences stabilize the downstream DENV2 and JEV cDNA clones and reduce the toxic nature of flavivirus cDNAs in bacteria. This knowledge can be applied to other RNA viruses or any unstable cDNA. Second, an in-depth understanding of flavivirus virology at the molecular level has not been achieved due to difficulties in manipulating flavivirus infectious cDNA clones. Easy manipulation of stable, infectious cDNA clones will be immensely useful for providing insight into viral replication at the molecular level. Third, it is known that the ease of handling infectious cDNA clones is important to provide a simple, reliable and cost-effective method for maintaining viruses and vaccine repositories (Kohara et al., 1986; Lai & Monath, 2003) . In particular, large-scale live attenuated vaccine cDNA clones can be easily obtained by our approach to test the efficacy of vaccine candidates. Our method will therefore facilitate vaccine development, especially for DNA vaccines.
METHODS
Cell lines and virus strains. Baby hamster kidney (BHK21) clone 15 cells were kindly provided by Dr P. Robert Beatty (Department of Molecular and Cell Biology, University of California at Berkeley, CA, USA) and cultured in alpha-MEM supplemented with 5 % FBS at 37 uC in a 5 % CO 2 incubator. DENV2 (Taiwanese DENV2 strain) (Lin et al., 1998) and JEV (RP-9 strain) were both kindly provided by C. L. Liao (Institute of Biomedical Sciences, National Defense Medical Center, Taiwan).
Bacteria, yeast methods, and strains. Frozen, competent E. coli strain C41, a derivative of BL21(DE3) (Miroux & Walker, 1996) , and strain STBL2 were purchased from Lucigen and Life Technologies, respectively. Strain C41 harbouring DENV2 or JEV infectious cDNA clones was cultured at either 25 uC or 30 uC in 26 YT medium (BD Bioscience). Standard yeast medium and methods were used (Burke & Kwast, 2000) . Saccharomyces cerevisiae YPH857 (Polo et al., 1997) was obtained from ATCC.
Plaque-forming assay. Plaque assay was conducted as described previously (Pu et al., 2011) . In brief, BHK21 clone 15 cells were infected for 2 h with DENV2 or JEV before overlay and the plaque was visualized with naphthol blue-black solution (0.1 % naphthol blueblack, 1.36 % sodium acetate and 6 % glacial acetic acid) (Morens et al., 1985) .
Preparation of viral RNAs and cDNAs by reverse transcription.
DENV2 and JEV viral RNA were purified using the Qiagen RNeasy kit as described in the manufacturer's protocol. Viral cDNA was synthesized by reverse transcription using the Transcriptor first strand cDNA synthesis kit (Roche Biochemical) with primers D2/39 or JEV/ 39 (Table S1 ) according to the manufacturer's protocol.
Construction of DNA-or RNA-launched infectious cDNA clones and various reporter constructs. The detailed methods for the construction of all clones are described in the Supplementary Methods. Primers are listed in Table S1 .
In vitro transcription and transfection. The plasmids pTight-SP6-DENV2, pGAL4-SP6-DENV2, pBamHI-SP6-DENV2 and pTight-SP6-JEV were first linearized with XbaI for DENV or KpnI for JEV. RNA transcript was generated with SP6 polymerase using mMESSAGE mMACHINE (Life Technologies) according to the manufacturer's protocol. Typical yields of the transcribed viral RNAs were approximately 5 mg. One hundred nanograms of full-length in-vitro-transcribed DENV2 or JEV viral RNA was transfected into 50 000 BHK21 cells using Lipofectamine 2000 (Life Technologies).
Indirect immunofluorescence to detect viral antigens. Cells were cultured and manipulated in 12-well plates. DENV2 prM protein and JEV E protein were detected by 2H2 antibody (mouse monoclonal HB-114; ATCC) (Kaufman et al., 1989) or 4G2 antibody (mouse monoclonal 4G2; ATCC) (Henchal et al., 1982) , respectively. The cells were then incubated with an Alexa Fluor 488 anti-mouse IgG antibody (Life Technologies). Images were acquired using a Leica DMIRB microscope equipped with CoolSNAP cooled CCD cameras and Empix Northern Ellipse image software.
Growth curve of virus replication. BHK21 clone 13 cells were infected with parental or transcript-derived DENV2 or JEV at a m.o.i. of 0.1 in 24-well plates. The supernatant from infected cells was removed daily and stored at 270 uC. DENV2 or JEV viral titres in each collected sample were determined through serial titration on BHK21 clone 15 cells.
